CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Core Viewpoint - CVRx, Inc. is set to release its first quarter 2025 financial and operating results on May 8, 2025, followed by a conference call to discuss these results [1] Company Overview - CVRx, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases [3] - The company's flagship product, Barostim™, is the first FDA-approved medical technology that utilizes neuromodulation to alleviate symptoms in heart failure patients [3] - Barostim is an implantable device that sends electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3] - The device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as CE Mark for heart failure and resistant hypertension in the European Economic Area [3]